PPMI @ AD/PD: April 2025

Onsite and Online Poster	
Bridget McMahon	PARKINSON'S PROGRESSION MARKERS INITIATIVE (PPMI): INVESTIGATING BIOMARKER DRIVEN PD PROGRESSION
Craig Stanley	MYPPMI: A WEB PORTAL FOR ENHANCING PARTICIPANT ENGAGEMENT AND DATA COLLECTION IN PARKINSON'S DISEASE CLINICAL TRIALS
Kathleen Poston	CONCORDANCE OF NEUROPATHOLOGIC DIAGNOSIS OF LEWY BODY DISEASE WITH BASELINE ALPHA-SYNUCLEIN SEED AMPLIFICATION ASSAY IN PPMI
Lynell Lemon	PARTICIPANT ENGAGEMENT INITIATIVE: IMPACT OF CENTRALIZED INTERN PROJECT TO COLLECT PARTICIPANT FEEDBACK FOR CLINICAL STUDY AIMED AT PARKINSON'S DISEASE PREVENTION
Lynell Lemon	TECHNICAL SUPPORT PROVISIONS FOR TIMELY REGISTRATION TO PARTICIPANT PORTAL: IMPACT UPON PARTICIPANTS INVOLVED IN STUDIES AIMED AT PARKINSON'S DISEASE (PD) PREVENTION
Paulina Gonzalez Latapi	BASELINE NEURONAL SYNUCLEIN DISEASE STAGE PREDICTS LONG TERM PROGRESSION IN SPORADIC PARKINSON'S DISEASE: AN 11-YEAR FOLLOW-UP STUDY
Tanya Simuni	PATH TO PREVENTION (P2P) THERAPEUTICS PLATFORM TRIAL DISEASE IN NSD STAGE 2B: STUDY UPDATE
Onsite Oral Presentation	
Dan Weintraub	USE OF ROBUST NORMING TO CREATE A SENSITIVE COGNITIVE SUMMARY SCORE IN DE NOVO PARKINSON'S DISEASE
Kathleen Poston	SYNERGISM ACROSS NEURODEGENERATIVE DISEASES USING BIOLOGICAL DEFINITIONS
Tanya Simuni	LONGITUDINAL CHANGE IN THE INTEGRATED STAGING SYSTEM OF NEURONAL ALPHA-SYNUCLEIN DISEASE (NSD-ISS) IN THE PPMI COHORT
Online On-Demand Oral Presentation	
Dan Weintraub	COGNITION IN EARLY-STAGE NEURONAL ALPHA-SYNUCLEIN DISEASE WITH HYPOSMIA
Ethan Brown	COMPARISON OF SMELL TESTING AND POLYSOMNOGRAPHY FOR DETECTION OF ALPHA-SYNUCLEIN PATHOLOGY IN INDIVIDUALS WITH DREAM ENACTMENT BEHAVIOR
Roger Gunn	CENTAMINES: STANDARDIZATION OF DOPAMINERGIC IMAGING MARKERS FOR CLINICAL TRIALS
Sarah Booker	CLINICAL CHARACTERISTICS OF SPORADIC PARKINSON'S DISEASE WITH NEGATIVE CEREBROSPINAL FLUID ALPHA-SYNUCLEIN SEED AMPLIFICATION ASSAY
Tom Tropea	RESEARCH INFORMATION DISCLOSURE IN THE PPMI STUDY: PARTICIPANT IMPRESSIONS IMMEDIATELY AFTER DISCLOSURE